We are live on
!
Find out more
PA
Profund Advisors Portfolio holdings
AUM
$2.72B
1-Year Est. Return
47.27%
This Fund
S&P 500
This Quarter
Est. Return
+2.46%
1 Year Est. Return
+47.27%
3 Year Est. Return
+155.16%
5 Year Est. Return
+217.35%
10 Year Est. Return
+932.28%
AUM
$1.42B
AUM Growth
–
Cap. Flow
+$1.43B
Cap. Flow
% of AUM
101.06%
Top 10 Holdings %
Top 10 Hldgs %
18.66%
Holding
1,386
New
1,386
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$41.1M |
| 2 |
Amgen
AMGN
|
+$40.3M |
| 3 |
AbbVie
ABBV
|
+$32.9M |
| 4 |
ExxonMobil
XOM
|
+$26.5M |
| 5 |
Biogen
BIIB
|
+$26.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.46% |
| 2 | Technology | 11.46% |
| 3 | Financials | 10.21% |
| 4 | Energy | 9.8% |
| 5 | Consumer Discretionary | 7.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$162B
| $40.4M | 2.86% |
+789,103
| New | +$41.1M |
|
|
2
Amgen
AMGN
$198B
| $38.3M | 2.7% |
+387,978
| New | +$40.3M |
|
|
3
AbbVie
ABBV
$448B
| $31.1M | 2.2% |
+751,991
| New | +$32.9M |
|
|
4
ExxonMobil
XOM
$640B
| $26.6M | 1.88% |
+294,785
| New | +$26.5M |
|
|
5
Biogen
BIIB
$29.2B
| $26.3M | 1.86% |
+122,387
| New | +$26.2M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $25.2M | 1.78% |
+431,270
| New | +$26M |
|
7
Apple
AAPL
$4.79T
| $23.1M | 1.63% |
+1,630,020
| New | +$25.1M |
|
8
Microsoft
MSFT
$2.9T
| $17.9M | 1.27% |
+519,123
| New | +$17M |
|
9
Johnson & Johnson
JNJ
$615B
| $17.7M | 1.25% |
+205,888
| New | +$17.5M |
|
10
Alphabet (Google) Class C
GOOG
$4.17T
| $17.5M | 1.23% |
+796,936
| New | +$16.9M |
|
11
Chevron
CVX
$384B
| $16.1M | 1.14% |
+136,464
| New | +$16.5M |
|
12
Pfizer
PFE
$141B
| $13.3M | 0.94% |
+501,860
| New | +$13.9M |
|
13
JPMorgan Chase
JPM
$926B
| $11.1M | 0.78% |
+209,794
| New | +$10.7M |
|
14
Amazon
AMZN
$2.63T
| $11M | 0.78% |
+793,980
| New | +$10.6M |
|
15
Wells Fargo
WFC
$262B
| $10.8M | 0.76% |
+262,004
| New | +$10.2M |
|
16
Vertex Pharmaceuticals
VRTX
$120B
| $10.7M | 0.76% |
+134,479
| New | +$9.9M |
|
17
Merck
MRK
$315B
| $10.1M | 0.71% |
+226,943
| New | +$10.1M |
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.34M | 0.66% |
+101,244
| New | +$9.76M |
|
19
Intel
INTC
$516B
| $9.18M | 0.65% |
+378,840
| New | +$8.95M |
|
20
Regeneron Pharmaceuticals
REGN
$68.3B
| $9.02M | 0.64% |
+40,118
| New | +$9.34M |
|
21
AT&T
T
$160B
| $8.46M | 0.6% |
+316,455
| New | +$8.79M |
|
22
Cisco
CSCO
$442B
| $8.45M | 0.6% |
+347,386
| New | +$7.82M |
|
23
Oracle
ORCL
$362B
| $8.33M | 0.59% |
+271,014
| New | +$8.99M |
|
24
SLB Ltd
SLB
$71.3B
| $8.21M | 0.58% |
+114,634
| New | +$8.48M |
|
25
Citigroup
C
$222B
| $7.76M | 0.55% |
+161,686
| New | +$7.77M |
|
Similar funds
MASUI
XL
MSL
CA
APSPRSPT
TAM
NCM
GC
Profund Advisors's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Profund Advisors, which disclosed 1,386 positions worth $1.42B. Its ten largest holdings account for 19% of the portfolio.
Its largest position is Gilead Sciences: 789,103 shares worth $40.4M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, followed by Technology and Financials.
- Profund Advisors's largest Q2 2013 buy was Gilead Sciences: 789,103 shares worth $40.4M.
- Profund Advisors's ten largest holdings make up 19% of its $1.42B portfolio in Q2 2013.
- Profund Advisors disclosed 1,386 positions in Q2 2013, its first 13F filing on record.
Based on Profund Advisors's 13F filing for Q2 2013, filed 25 Jul 2013.